Photolysis of tolfenamic acid in aqueous and organic solvents: a kinetic study
SH Kazi, MA Sheraz, Z Anwar, SG Musharraf… - RSC …, 2024 - pubs.rsc.org
Tolfenamic acid (TA) is a non-steroidal anti-inflammatory drug that was studied for its
photodegradation in aqueous (pH 2.0–12.0) and organic solvents (acetonitrile, methanol …
photodegradation in aqueous (pH 2.0–12.0) and organic solvents (acetonitrile, methanol …
Long non-coding RNAs sponging microRNAs with efficacy in preclinical in vivo models of esophageal squamous cell cancer
UH Weidle, A Nopora - Anticancer Research, 2022 - ar.iiarjournals.org
Esophageal cancer is of two subtypes: Esophageal adenocarcinoma and esophageal
squamous cell carcinoma (ESCC). Both are associated with a dismal prognosis. Therefore …
squamous cell carcinoma (ESCC). Both are associated with a dismal prognosis. Therefore …
A prognosis model for predicting immunotherapy response of esophageal cancer based on oxidative stress-related signatures
J Guo, C Tong, J Shi, X Li, X Chen - Oncology Research, 2023 - pmc.ncbi.nlm.nih.gov
Oxidative stress (OS) is intimately associated with tumorigenesis and has been considered a
potential therapeutic strategy. However, the OS-associated therapeutic target for …
potential therapeutic strategy. However, the OS-associated therapeutic target for …
Arntl-induced upregulation of DUSP1 inhibits tumor progression in esophageal squamous cell carcinoma by inactivating ERK signaling
J Wang, Q Jia, J Sun, S Wu, L Wei… - Cancer Biology & …, 2024 - Taylor & Francis
Background Esophageal squamous cell carcinoma (ESCC) is a primary histological type of
esophageal carcinoma with high morbidity. Aryl hydrocarbon receptor nuclear translocator …
esophageal carcinoma with high morbidity. Aryl hydrocarbon receptor nuclear translocator …
XRCC2 knockdown effectively sensitizes esophageal cancer to albumin-paclitaxel in vitro and in vivo
J Xu, X Liu, Z Huang, T Lu, Y Zhang, D Cai, X Li - Biochemical Genetics, 2024 - Springer
Esophageal cancer (EC), a prevalent malignancy, has a high incidence and mortality. X-ray
repair cross complementing 2 (XRCC2) functions on DNA damage and repair that works the …
repair cross complementing 2 (XRCC2) functions on DNA damage and repair that works the …
多西他赛联合洛铂同步调强放疗对中晚期食管癌近远期疗效, 肿瘤标志物和生存质量的影响.
刘涛， 林晓明， 李浩然， 杨翔峰… - Progress in Modern …, 2024 - search.ebscohost.com
摘要目的: 评价多西他赛(DTX) 联合洛铂(LBP) 同步调强放疗(IMRT) 对中晚期食管癌(EC)
近远期疗效, 肿瘤标志物和生存质量的影响. 方法: 选入我院2018 年1 月~ 2022 年6 …
近远期疗效, 肿瘤标志物和生存质量的影响. 方法: 选入我院2018 年1 月~ 2022 年6 …